Elan Maxipime Shortage Due To Manufacturing Suspension
This article was originally published in The Pink Sheet Daily
Maxipime manufacturer Bristol-Myers Squibb says it temporarily stopped manufacturing cefepime in January due to documentation issues related to bulk manufacturing. FDA accepts Bristol request to release additional product under an amended filing April 12, Bristol says.
You may also be interested in...
Additional audiences for the pain product are being targeted following a "quiet" launch at the beginning of the year.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter